580 related articles for article (PubMed ID: 27322743)
1. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
2. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
3. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
5. RANKL/RANK control Brca1 mutation- .
Sigl V; Owusu-Boaitey K; Joshi PA; Kavirayani A; Wirnsberger G; Novatchkova M; Kozieradzki I; Schramek D; Edokobi N; Hersl J; Sampson A; Odai-Afotey A; Lazaro C; Gonzalez-Suarez E; Pujana MA; Cimba F; Heyn H; Vidal E; Cruickshank J; Berman H; Sarao R; Ticevic M; Uribesalgo I; Tortola L; Rao S; Tan Y; Pfeiler G; Lee EY; Bago-Horvath Z; Kenner L; Popper H; Singer C; Khokha R; Jones LP; Penninger JM
Cell Res; 2016 Jul; 26(7):761-74. PubMed ID: 27241552
[TBL] [Abstract][Full Text] [Related]
6. Out-RANKing BRCA1 in Mutation Carriers.
Nolan E; Lindeman GJ; Visvader JE
Cancer Res; 2017 Feb; 77(3):595-600. PubMed ID: 28104682
[TBL] [Abstract][Full Text] [Related]
7. RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
Rao S; Cronin SJF; Sigl V; Penninger JM
Trends Cell Biol; 2018 Mar; 28(3):213-223. PubMed ID: 29241686
[TBL] [Abstract][Full Text] [Related]
8. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
9. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
10. NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of
Sau A; Cabrita MA; Pratt MAC
Cancer Prev Res (Phila); 2018 Feb; 11(2):69-80. PubMed ID: 29101208
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Cell Cycle; 2017 Jun; 16(11):1022-1028. PubMed ID: 28387573
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
13. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
14. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
[TBL] [Abstract][Full Text] [Related]
15. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
16. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
18. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 mutation influences progesterone response in human benign mammary organoids.
Davaadelger B; Choi MR; Singhal H; Clare SE; Khan SA; Kim JJ
Breast Cancer Res; 2019 Nov; 21(1):124. PubMed ID: 31771627
[TBL] [Abstract][Full Text] [Related]
20. Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.
Sau A; Lau R; Cabrita MA; Nolan E; Crooks PA; Visvader JE; Pratt MA
Cell Stem Cell; 2016 Jul; 19(1):52-65. PubMed ID: 27292187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
